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This retrospective matched cohort study used routinely 
collected smoking cessation treatment programme data linked 
to population- based administrative and demographic databases 
housed at ICES (https://www. ices. on. ca). ICES is an indepen-
dent, non- profit research institute whose legal status under 
Ontario’s health information privacy law allows it to collect 
and analyse healthcare and demographic data, without consent, 
for health system evaluation and improvement. These data sets 
were linked using unique encoded identifiers and analysed at 
ICES. The study is reported in accordance with REporting of 
studies Conducted using Observational Routinely- collect Data 
(RECORD) guidelines.21
Setting
Canada’s province of Ontario has a population of 13.5 million,22 
with 1.8 million smoking cigarettes daily or occasionally 
(1.1 million men and 700 000 women).23 Medically required 
healthcare services are paid for by the province through the 
Ontario Health Insurance Plan (OHIP). The Smoking Treatment 
for Ontario Patients (STOP) programme delivers smoking cessa-
tion treatment at partnering healthcare organisations and is also 
publicly funded. Patients can enrol through either practitioner- 
referral or self- referral. It is a pragmatic, real- world programme 
in which treatment, consisting of nicotine replacement therapy 
for up to 26 weeks and behavioural counselling, is individually 
tailored. STOP is effective with 26% of patients reporting absti-
nence at 6- month follow- up.24 Additional details are provided in 
online supplemental appendix S1.
Study population
The treatment cohort initiated smoking cessation treatment with 
the STOP programme between 01 July 2011 and 31 December 
2012. Patient- level data were previously linked to ICES data 
holdings using probabilistic and deterministic linkage with a 96% 
linkage rate.25 Ninety per cent of patients who enrolled during 
the study time frame consented to linkage. For any patient who 
enrolled more than once, data related to their first enrolment 
was used. A treated patient’s index date was the date of enrol-
ment. Patients accessed treatment at one of three organisation 
types with greater than 99% attending a primary care clinic.
The control cohort of Ontario smokers, not using STOP 
services, was assembled using the Canadian Community Health 
Survey (CCHS), that has been linked to ICES databases. The 
CCHS is a cross- sectional survey conducted by Statistics Canada 
that collects self- reported health- related data from about 
130 000 Canadians in every 2- year cycle.26 It is representative 
of approximately 98% of the Canadian population aged 12 and 
older residing in private households; detailed survey method-
ology is reported elsewhere.27 Approximately 84.7% of respon-
dents residing outside the province of Quebec agreed to linkage 
of their data, with variation across survey years.28 We used three 
cycles of the CCHS to increase sample size29 30: 2007/2008, 
2009/2010 and 2011/2012. For any respondent in multiple 
cycles, data from their most recent survey was used to better 
align with the time frame for the treatment cohort. A respon-
dent’s index date was the date they completed the survey. The 
study time frame was selected because it marked initiation of 
these STOP models, had linked CCHS data from which to select 
controls and allowed up to 5 years of follow- up time.
In both cohorts, individuals were excluded if sex was missing, 
they had an invalid record, they were ineligible for OHIP 
coverage, did not reside in Ontario at index date, had a date of 
death that preceded index date, were not smoking daily or occa-
sionally, age was less than 12 or greater than 105 years or lacked 
a full 2- year lookback window. Additionally, individuals in the 
potential treatment cohort that also completed the CCHS were 
excluded if they reported not smoking in the survey.
Each treated individual was matched to one control individual 
using hard (sex and age at index ±2 years) and propensity score 
matching. The propensity score was obtained using multivari-
able logistic regression with the following covariates: age at 
index date (continuous with linear and quadratic terms), educa-
tion quintile, household income quintile, number of cigarettes 
smoked per day at index (continuous with linear and quadratic 
terms), age first started smoking (continuous with linear and 
quadratic terms), number of Aggregated Diagnostic Groups 
(ADGs) categorical (0–5, 6–9, 10+) and the rate of ED visits and 
rate of hospitalisations in the 2 years prior to index date. Missing 
values of categorical variables were coded as a distinct category 
and were included in the propensity score. Missing values of 
continuous variables were not included in the propensity score 
and patients were not matched. Once propensity scores were 
estimated, 1:1 matching was completed using a greedy algorithm 
with no replacement based on a calliper width of 0.2 SD of the 
logit of the estimated propensity score.31
Healthcare service utilisation outcomes
The primary outcomes were the rate of outpatient visits, rate 
of ED visits and rate of all- cause hospital admissions. For each 
outcome, every individual could experience multiple occur-
rences throughout their observation period. Times to each occur-
rence were measured in years from index date until 31 March 
2017, death or loss of OHIP eligibility, whichever occurred 
first. Online supplemental table S1 describes the derivation of 
outcome variables.
Baseline characteristics
The following self- reported descriptive characteristics were 
measured at index in the treatment programme intake data 
or CCHS survey: frequency of smoking, number of cigarettes 
smoked per day and age first tried smoking. Duration of 
smoking was calculated using an individual’s age at index, from 
ICES data sets, and age of smoking initiation, from STOP and 
CCHS surveys.
Additional individual- level characteristics measured at index 
were derived via linkage to ICES data sets: age at index, sex 
and migrant status. The following prevalent comorbidities were 
obtained from existing ICES- derived data sets built by applying 
standardised algorithms: diabetes, hypertension, COPD, asthma, 
congestive heart failure and myocardial infarction. Ecological- 
level measures of neighbourhood educational, employment and 
income quintiles, and rurality were estimated using data from 
the 2006 Canadian census32 and were applied to individuals 
according to the smallest geographical census area in which 
they resided at index. Prior healthcare utilisation, and comor-
bidity burden derived from ADG scores, were estimated using a 
2- year lookback window from index date. The Johns Hopkins 
ACG® System Aggregated Diagnosis Groups (Version 10) 
provide a numeric method for grouping diagnostic codes similar 
in severity and likelihood of persistence. They have previously 
been validated for use in the adult Ontario population.33 Online 
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Statistical analyses
Distributions of baseline characteristics were reported using 
frequencies and percentages for categorical measures and mean 
and SD for continuous measures. Balance between treated and 
control groups was assessed using standardised mean differ-
ences (SMD), where a SMD of greater than 10%34 implies a 
meaningful imbalance. Initial crude analyses were conducted by 
calculating the total number of ED visits, outpatient visits and 
hospital admissions, and corresponding crude rates (per person- 
year) with CIs for rates generated under Poisson assumptions.35 
Based on a recurrent event and counting process framework, for 
each outcome, the non- parametric mean cumulative function 
approach was used to illustrate the mean cumulative number of 
events as a function of time, along with 95% CIs.36
Multivariable Andersen- Gill (AG) recurrent event regression 
models were implemented on our matched cohort to examine 
the association between exposure to smoking cessation treatment 
and the rate of each outcome.37–39 Attained age was used as the 
time scale. For each outcome, the event times for an individual 
were the times from their index date to the date of each occur-
rence. Individuals were right- censored at the end of their obser-
vation window. A robust sandwich variance estimation approach 
was used to account for the matched design. As decided a priori, 
characteristics that remained unbalanced in our matched cohort 
at baseline between treated and control groups were included 
as covariates in multivariable AG regression models to account 
for possible confounding. Interactions with treatment (our main 
exposure) and comorbidities (COPD and hypertension) were 
also examined to determine if the association between exposure 
to the smoking cessation treatment and outcome rates varied by 
presence of comorbidity.
All analyses discussed above were conducted on the overall 
matched cohort and stratified by sex. Analyses were performed 
using the SAS Enterprise Guide V.7.12 (2016, SAS Institute). 
Statistical tests were two- sided; an alpha of less than 0.05 was 
considered statistically significant.
RESULTS
Derivation and baseline characteristics by cohort
Between 01 July 2011 and 31 December 2012, 13 561 Ontario 
smokers used the smoking cessation treatment programme and 
had data linked to ICES data holdings. After applying the exclu-
sion criteria described above, there were 12 965 individuals in 
the potential treatment cohort available for matching. Of the 19 
771 CCHS respondents who were smokers, 19 260 were in the 
potential control cohort and available to serve as matches (see 
online supplemental figure S1).
Prior to matching, the potential treatment and control cohorts 
were unbalanced on several demographic characteristics: the 
potential treatment cohort smoked more, had a greater number 
of comorbidities and a higher rate of prior healthcare utilisation 
(see online supplemental tables S2 and S3). Of the 12 965 indi-
viduals in the potential treatment cohort, 9951 were matched 
to a control smoker. After matching, the majority of baseline 
characteristics became well matched (SMD <0.1); differences 
remained in smoking frequency and comorbidities (see table 1 
and online supplemental table S4). The median follow- up time 
in the treatment cohort and control cohorts were 4.8 and 6.1 
years, respectively.
Healthcare service use during follow-up
Of the 9951 individuals in the treatment cohort, 9793 (98.4%), 
7944 (79.8%) and 3499 (35.2%) had at least one outpatient visit, 
Table 1 Baseline characteristics and prior healthcare service use of 








Age, mean±SD 48.96±14.18 48.98±14.17 0
Sex
  Female 5257 (52.8) 5257 (52.8) 0
  Male 4694 (47.2) 4694 (47.2) 0
Education quintile
  Missing 556 (5.6) 541 (5.4) 0.01
  Q1 (lowest) 690 (6.9) 661 (6.6) 0.01
  Q2 1485 (14.9) 1461 (14.7) 0.01
  Q3 1989 (20) 1977 (19.9) 0
  Q4 2523 (25.4) 2548 (25.6) 0.01
  Q5 (highest) 2708 (27.2) 2763 (27.8) 0.01
Employment quintile
  Missing 556 (5.6) 541 (5.4) 0.01
  Q1 (lowest) 2196 (22.1) 2234 (22.5) 0.01
  Q2 2013 (20.2) 1876 (18.9) 0.03
  Q3 1787 (18) 1915 (19.2) 0.03
  Q4 1745 (17.5) 1746 (17.5) 0
  Q5 (highest) 1654 (16.6) 1639 (16.5) 0
Rurality + neighbourhood 
income quintile
  Missing 19 (0.2) 19 (0.2) 0
  Rural 2381 (23.9) 2383 (23.9) 0
  Urban Q1 (lowest) 2196 (22.1) 2166 (21.8) 0.01
  Urban Q2 1579 (15.9) 1597 (16) 0
  Urban Q3 1431 (14.4) 1477 (14.8) 0.01
  Urban Q4 1336 (13.4) 1321 (13.3) 0
  Urban Q5 (highest) 1009 (10.1) 988 (9.9) 0.01
Migrant status
  Immigrant* 262 (2.6) 267 (2.7) 0
  Non- immigrant 9689 (97.4) 9684 (97.3) 0
Smoking characteristics
Frequency of smoking
  Daily 9745 (97.9) 9133 (91.8) 0.28
  Occasional 206 (2.1) 818 (8.2) 0.28
Cigarettes per day, mean±SD 17.82±9.77 17.56±9.56 0.03
Age first tried smoking, 
mean±SD
15.82±4.81 15.69±4.67 0.03





  COPD 2985 (30) 2018 (20.3) 0.23
  Hypertension 2863 (28.8) 2694 (27.1) 0.04
  Diabetes 1515 (15.2) 1146 (11.5) 0.11
  Asthma 1882 (18.9) 1474 (14.8) 0.11
  Cancer 448 (4.5) 400 (4) 0.02
  Myocardial infarction 332 (3.3) 248 (2.5) 0.05
  Congestive heart failure 235 (2.4) 193 (1.9) 0.03
No. ADG comorbidities, mean±SD 5.84±3.43 5.45±3.63 0.11
  0–5 5149 (51.7) 5177 (52) 0.01
  6–9 3314 (33.3) 3355 (33.7) 0.01
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ED visit or hospitalisation, respectively. Similarly, of the 9951 
individuals in the control cohort, 9606 (96.5%), 7844 (79.8%) 
and 3815 (38.3%) had at least one outpatient visit, ED visit or 
hospitalisation, respectively. Table 2 shows the crude rates of 
outpatient visits, ED visits and hospitalisations in the matched 
treatment and control cohorts, overall and by sex. Patterns were 
similar for outpatient and ED visits: the rates were higher in the 
treatment cohort than in the control cohort. This was observed 
in the overall and sex- stratified cohorts. Within treatment and 
control cohorts, crude rates were higher in women than in men. 
For hospitalisations, the overall pattern observed was similar to 
that for outpatient and ED visits, but with differences attenu-
ated. These findings are depicted visually in figure 1, which plots 
the estimated mean cumulative number of outpatient visits, ED 
visits and hospitalisations during follow- up (and 95% CIs) for 
the treatment and matched control cohorts, both overall and by 
sex. Point estimates at 2 and 5 years are provided; for example, 
5 years after index date the cumulative number of outpatient 
visits in the overall cohorts were 35.02 and 31.16 among the 
treatment and control cohorts, respectively.
Adjusted association between smoking cessation treatment 
and healthcare service use
Compared with matched controls, after controlling for poten-
tial confounders, patients in the overall treatment cohort had 
significantly greater rates of each of the three healthcare service 
use outcomes. The magnitude of the positive associations was 
modest. Stratified by sex, a positive association between smoking 
cessation treatment and healthcare service use was observed 
for ED visits among men only, and for outpatient visits among 
women and among men, but the magnitude of association was 
greater in men. Findings were inconclusive as to whether there 
was an association observed for hospitalisations among women 
or among men (see table 2).
Effect modification of the association between smoking cessa-
tion treatment and healthcare service use by prevalent comor-
bidity was found for outpatient visits in the overall cohort 
(p=0.006), with no difference in rates versus controls in patients 
with prevalent hypertension (figure 2). These effects were 
primarily driven by differences in women, among whom rates 
were significantly greater versus controls in patients with neither 
hypertension nor COPD. In patients with either one or both 
conditions, findings were inconclusive as to whether or not there 
was a difference between treatment and control cohorts. Statisti-
cally significant effect modification was also found in the overall 
cohort for hospitalisations, with greater rates versus controls in 
patients with neither prevalent hypertension nor COPD, and in 
patients with COPD only, than among patients with hyperten-
sion only or both conditions; p=0.05). The complete multivari-
able regression estimates are available in online supplemental 
tables S5–S13.
DISCUSSION
In this study of 19 902 matched smokers, we found a slightly 
greater rate of outpatient visits, ED visits and hospitalisations 
among smokers who had accessed the smoking cessation treat-
ment programme compared with smokers who did not. In anal-
yses stratified by sex, the increased rate of outpatient visits was 
observed among men and women, while the increased rate of ED 
visits was restricted to men only. The increased rate of hospital-
isations was observed in the overall cohort but not when strati-
fied by sex.
The difference in healthcare service use between the inter-
vention and matched control groups was greater among 
those patients who did not have pre- existing comorbid condi-
tions—and lesser among patients who did. The implication is 
that for patients who are already engaged with the healthcare 
system for the diagnosis and treatment of chronic disease, the 
addition of smoking cessation treatment has less impact on the 
subsequent rate of healthcare use. This is an important finding 
because COPD and hypertension were common in the matched 
cohorts and are common in people who smoke generally.
Our findings contrast with prior studies that showed a decrease 
in healthcare service use associated with smoking cessation treat-
ment.8–12 14 A possible explanation for the contradictory findings 
may lie with differences in treatment setting, patient population 
and healthcare service outcome measures in our and most prior 
studies. Patients in primary care settings are less likely to have 
severe comorbidities requiring hospitalisation; indeed 83.2% 
of individuals in our matched treatment cohort had not been 
hospitalised in the 2 years prior to index date. By focusing on 
hospitalised patients, and re- hospitalisation outcome measures, 
previous investigations have focused on narrower populations, 
and possibly ones likely to benefit from an intervention in the 
short- term during a teachable moment.13 In the singular prior 
study14 that also had a general population of smoking cessa-
tion treatment users, the likelihoods of hospitalisations for two 






Rate of healthcare service 
use ppy†
Outpatient visits (mean±SD) 6.61±8.62 6.16±7.64 0.06
ED visits (mean±SD) 0.89±1.40 0.83±1.50 0.04
Hospitalisations (mean±SD) 0.13±0.38 0.12±0.37 0.02
Number (%) are reported unless otherwise noted.
*Includes immigrants and refugees.
†During 2- year period up to index date.
ADG, Aggregated Diagnostic Groups; COPD, chronic obstructive pulmonary 
disease; ED, emergency department; ppy, per person year; Q, quintile; SMD, 
standardised mean difference.
Table 1 Continued
Table 2 Crude rates and adjusted associations between smoking 
cessation treatment and healthcare service use outcomes in Ontario, 
Canada, between 2011 and 2017, in matched treatment and control 










Outpatient visits Overall 7.52±10.26 6.73±8.42 1.10 (1.06 to 1.14)
  Female 8.03±10.06 7.44±8.40 1.08 (1.03 to 1.12)
  Male 6.95±10.46 5.93±8.38 1.13 (1.07 to 1.19)
ED visits Overall 1.03±1.78 0.88±1.67 1.08 (1.03 to 1.13)
  Female 1.06±1.77 0.95±1.72 1.05 (0.98 to 1.12)
  Male 0.99±1.80 0.80±1.60 1.13 (1.05 to 1.20)
Hospitalisations Overall 0.23±0.81 0.21±0.68 1.09 (1.02 to 1.18)
  Female 0.23±0.84 0.21±0.73 1.09 (1.00 to 1.19)
  Male 0.24±0.78 0.20±0.63 1.10 (0.98 to 1.24)
Bolded rate ratios are significant at p<0.05.
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decreased, but no decrease or increase for 13 other cause- specific 
hospitalisations or all- cause hospitalisations were observed. The 
prior literature, with its dearth of directly relevant studies, does 
not provide a strong context into which to place our results. 
The related literature, however, linking smoking status itself 
with healthcare service utilisation is relevant. Relative to never 
smokers, current smokers have greater healthcare service util-
isation in most,40–48 but not all,41 42 49 analyses. While there is 
some evidence that healthcare service use is also lower among 
former smokers relative to current smokers,40 43 in various anal-
yses smoking cessation is associated with a short- term increase 
in usage that remains above that of, similar to, or below that of, 
current smokers,41–43 46 47 or is not associated with any increase 
or decrease.41 43 50 These findings provide conflicting and indirect 
evidence that smoking cessation may reduce healthcare service 
use but that reductions may not be realised for some time.
In our study, the rate of healthcare service use in the 2 years 
prior to the index date was similar in the matched cohorts. Since 
the number of patients who quit smoking is likely greater in 
the treatment cohort than the control cohort,13 24 51 52 if quit-
ting smoking results in decreased healthcare service use then it 
follows that healthcare service use should be lower on average 
in the treatment cohort than the control cohort. As that was 
not observed, these findings suggest that, in the population of 
Ontarian smokers, either the beneficial effect of smoking cessa-
tion treatment on healthcare service use among those patients 
who achieve abstinence is outweighed by the lack of such effect 
among the majority of patients who do not achieve abstinence, or 
there is no such beneficial effect during the first 5 years following 
initiation of smoking cessation treatment.
Further research should build on these findings. It is unclear 
in the observed increased healthcare service use is a positive or 
negative consequence of smoking cessation treatment and what 
mechanisms underly the observed association. Our study lacked 
longitudinal measures of smoking status or complex smoking 
cessation trajectories due to the absence of such data in routinely 
collected administrative healthcare data. Longitudinal studies 
of smokers, if linked to administrative healthcare data and of 
sufficient size to have robust numbers of treatment seeking 
smokers, could help address these important gaps. Additionally, 
patients in Ontario do not incur personal costs (eg, service fees 
or copays) to access ED, outpatient or hospitalisation services; 
further research is warranted to assess the impact of smoking 
cessation treatment in jurisdictions where these barriers to 
healthcare service use exist.
Assessing the healthcare system implications associated with 
uptake of available smoking cessation treatment services is 
important for tobacco control experts and healthcare system 
planners internationally. Relatively few smokers who attempt 
to quit use available smoking cessation resources.53 However, 
tobacco control policies, such as increased taxation, anti- 
smoking media campaigns and comprehensive smoke- free poli-
cies, increase the demand for tobacco dependence treatment and 
therefore, continued capacity building and adoption of FCTC 
guidelines may both increase interest in smoking cessation treat-
ment and provide guidelines for implementation in primary care 
settings.53
Strengths of this study include the use of a non- treatment 
seeking control group. Such a control group cannot be derived 
from typical administrative healthcare data and was possible due 
to the prior linkage of very large population based health survey 
data. Additionally, use of a concurrent control group allowed for 
avoidance of temporal differences that can impact results when 
a pre–post design is used. Lastly, all outcomes in both treatment 
and control groups were ascertained identically using healthcare 
administrative databases therefore bias resulting from differen-
tial missing data are unlikely.
This study also has limitations. First, the exposure, which 
necessarily requires both motivation to quit smoking and a will-
ingness to engage with smoking cessation treatment, cannot 
be randomised. Although we accounted for a range of factors 
through hard and propensity score matching and adjustment 
for potential confounders, there is potential for unmeasured or 
residual confounding. Second, the statistical analyses necessarily 
Figure 1 Estimated mean cumulative number of outpatient visits, emergency department visits and hospitalisations in Ontario, Canada, between 
2011 and 2017, in matched treatment and control cohorts, overall and stratified by sex. *Mean cumulative number of hospitalisations for women in 
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were restricted to treatment patients who were successfully 
matched to a control, thus including the majority of, but not all, 
patients. We combined cycles of the CCHS in order to increase 
the number of potential matches, but residual differences may 
have occurred affecting generalisability. Third, the length of 
follow- up in our study is insufficient to ascertain any long- term 
impacts of smoking cessation treatment on healthcare service 
utilisation.
CONCLUSIONS
Primary care- based smoking cessation treatment in Ontario, 
Canada, was associated with a small but significant increase in 
the rate of all- cause outpatient visits, ED visits and hospitalisa-
tions, but there was significant heterogeneity in some outcomes 
depending on sex and the presence of comorbid COPD and 
hypertension.
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